WE here all the time that we have some kind of deal with Core One Labs. They sure keep improving what they are doing.
L
OTC: CLABF
Frankfurt: LD62, WKN: A14XHT
Leading Microbiologist, Dr. Robert E.W. Hancock Appointed As Executive
Chairman of Core One Labs Inc.
Vancouver, British Columbia, Canada – January 7, 2021 – Core One Labs Inc. (CSE: COOL),
(OTC: CLABF), (Frankfurt: LD62, WKN: A14XHT) (the “Company” or “Core One”) is pleased to
announce the appointment of Dr. Robert E.W. Hancock as Executive Chairman of the Company,
effective January 6, 2021.
Dr. Hancock is an internationally renowned academic in Microbiology and Immunology – having
bestowed upon him the title of UBC Killam Professor of Microbiology and Immunology - is the
Director of the University of British Columbia’s R.E.W Hancock Laboratory at the Centre for
Microbial Diseases and Immunity Research, as well as a former Associate Faculty Member of the
Wellcome Trust Sanger Institute in Cambridge, UK - one of the top 3 Genome campuses
worldwide.
Receiving his PhD from the University of Adelaide, in 1975, Dr. Hancock has become one of the
World’s most highly cited International Scientific Indexing (ISI) research authors, with more than
108,000 citations, and has published more than 780 papers and reviews in his fields of expertise.
Dr. Hancock is the holder of the important position of the Canadian Research Chair in Health and
Genomics, as appointed by the Government of Canada, and is also a recipient of the Order of
Canada, in addition to numerous other major health research awards.
Dr. Hancock is a co-founder of several companies, both private and public, including Micrologix,
Inimex, ABT Innovations, and Sepset Biotherapeutics, and is the CEO of Vocan Biotechnologies
Inc. (“Vocan”), a biotechnology company that Core One acquired on December 31, 2020.
Vocan is focused on advancing the knowledge of natural-based medicines for the treatment of
mental health illnesses, including addictions, and has identified a patentable method of producing
psilocybin, the active ingredient in psychotropic mushrooms. With the acquisition of Vocan, the
Company is in the process of preparing to produce pharmaceutical grade psilocybin for use by
researchers engaging in clinical trials, as well as for the recreational and micro-dosing markets.
Dr. Hancock’s role as CEO for Vocan Biotechnologies, positions him as the best fit to lead the
Company as Executive Chairman, and provide direction to the Company on its path to becoming
a leader in the area of psychedelics as alternative medicines.
"I am honored to be joining Core One labs as the Chair of their Board. The Company's
innovative business strategy and strong leadership team will position it to grow into one
of the largest and most influential companies addressing the health and social benefits
of safe psychedelic compounds.", stated Dr. Hancock.
“We are excited to welcome Dr. Hancock to the Company as Executive Chairman. I look forward
to working with him closely as his nearly 40 years of leadership in microbiology research will be
vital to guiding our strategic initiatives in the alternative medicine market. His cutting edge
research, and focus on producing low cost biosynthesized psilocybin at a large scale is a driving
force behind Core One’s position as a leader in the space” stated Joel Shacker CEO of the
Company.
Dr. Hancock’s appointment to the Company’s Board of Directors fills the vacancy created by
Casey Fenwick, who has resigned as a director of the Company effective immediately to focus
on other ventures. The board of directors of the Company thanks Mr. Fenwick for his service to
the Company.
About Core One Labs Inc.
Core One Labs Inc. is a research and technology company focused in life sciences and on
bringing psychedelic medicines to market through novel delivery systems and psychedelic
assisted psychotherapy. The Company has developed a patent pending thin film oral strip (the
“technology”) which dissolves instantly when placed in the mouth and delivers organic molecules
in precise quantities to the bloodstream, maintaining excellent bioavailability. With this technology,
the Company intends to further develop its IP technology to focus on delivering psychedelic
molecules with an initial focus on psilocybin. Core One also holds an interest in walk-in medical
clinics which maintain a database of over 200,000 patients combined. Through research and
development in these clinics, including the integration of its intellectual property related
to psychedelic treatments and novel drug therapies, the Company intends to work
towards regulatory approval for research that advances psychedelic-derived treatments
for mental health disorders.
Core One Labs Inc.
Joel Shacker
Chief Executive Officer
FOR MORE INFORMATION, PLEASE CONTACT:
info@core1labs.com
1-866-347-5058
Cautionary Disclaimer Statement:
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy
or accuracy of the content of this news release.
Information set forth in this news release contains forward-looking statements that are based on
assumptions as of the date of this news release. These statements reflect management’s current estimates,
beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions
that all forward looking statements are inherently uncertain and that actual performance may be affected
by a number of material factors, many of which are beyond the Company’s control. Such factors include,
among other things: risks and uncertainties relating to the Company’s limited operating history and the need
to comply with environmental and governmental regulations. In addition, marijuana remains a Schedule I
drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the
US Justice Department from spending federal funds to interfere with the implementation of state medical
marijuana laws, this prohibition must be renewed each year to remain in effect. Accordingly, actual and
future events, conditions and results may differ materially from the estimates, beliefs, intentions and
expectations expressed or implied in the forward-looking information. Except as required under applicable
securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking
information. In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and
Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs
and Substances Act (Canada) without a prescription. Health Canada has not approved psilocybin as a drug
for any indication. Core One Labs Inc. does not have any direct or indirect involvement with illegal selling,
production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One
Labs Inc. believes psychedelic substances can be used to treat certain medical conditions, it does not
advocate for the legalization of psychedelics substances for recreational use. Core One Labs Inc. does not
deal with psychedelic substances, except within laboratory and clinical trial settings conducted within
approved regulatory framework
https://www.sedar.com/DisplayCompanyDocuments...o=00031206
TOODLES
L
OTC: CLABF
Frankfurt: LD62, WKN: A14XHT
Leading Microbiologist, Dr. Robert E.W. Hancock Appointed As Executive
Chairman of Core One Labs Inc.
Vancouver, British Columbia, Canada – January 7, 2021 – Core One Labs Inc. (CSE: COOL),
(OTC: CLABF), (Frankfurt: LD62, WKN: A14XHT) (the “Company” or “Core One”) is pleased to
announce the appointment of Dr. Robert E.W. Hancock as Executive Chairman of the Company,
effective January 6, 2021.
Dr. Hancock is an internationally renowned academic in Microbiology and Immunology – having
bestowed upon him the title of UBC Killam Professor of Microbiology and Immunology - is the
Director of the University of British Columbia’s R.E.W Hancock Laboratory at the Centre for
Microbial Diseases and Immunity Research, as well as a former Associate Faculty Member of the
Wellcome Trust Sanger Institute in Cambridge, UK - one of the top 3 Genome campuses
worldwide.
Receiving his PhD from the University of Adelaide, in 1975, Dr. Hancock has become one of the
World’s most highly cited International Scientific Indexing (ISI) research authors, with more than
108,000 citations, and has published more than 780 papers and reviews in his fields of expertise.
Dr. Hancock is the holder of the important position of the Canadian Research Chair in Health and
Genomics, as appointed by the Government of Canada, and is also a recipient of the Order of
Canada, in addition to numerous other major health research awards.
Dr. Hancock is a co-founder of several companies, both private and public, including Micrologix,
Inimex, ABT Innovations, and Sepset Biotherapeutics, and is the CEO of Vocan Biotechnologies
Inc. (“Vocan”), a biotechnology company that Core One acquired on December 31, 2020.
Vocan is focused on advancing the knowledge of natural-based medicines for the treatment of
mental health illnesses, including addictions, and has identified a patentable method of producing
psilocybin, the active ingredient in psychotropic mushrooms. With the acquisition of Vocan, the
Company is in the process of preparing to produce pharmaceutical grade psilocybin for use by
researchers engaging in clinical trials, as well as for the recreational and micro-dosing markets.
Dr. Hancock’s role as CEO for Vocan Biotechnologies, positions him as the best fit to lead the
Company as Executive Chairman, and provide direction to the Company on its path to becoming
a leader in the area of psychedelics as alternative medicines.
"I am honored to be joining Core One labs as the Chair of their Board. The Company's
innovative business strategy and strong leadership team will position it to grow into one
of the largest and most influential companies addressing the health and social benefits
of safe psychedelic compounds.", stated Dr. Hancock.
“We are excited to welcome Dr. Hancock to the Company as Executive Chairman. I look forward
to working with him closely as his nearly 40 years of leadership in microbiology research will be
vital to guiding our strategic initiatives in the alternative medicine market. His cutting edge
research, and focus on producing low cost biosynthesized psilocybin at a large scale is a driving
force behind Core One’s position as a leader in the space” stated Joel Shacker CEO of the
Company.
Dr. Hancock’s appointment to the Company’s Board of Directors fills the vacancy created by
Casey Fenwick, who has resigned as a director of the Company effective immediately to focus
on other ventures. The board of directors of the Company thanks Mr. Fenwick for his service to
the Company.
About Core One Labs Inc.
Core One Labs Inc. is a research and technology company focused in life sciences and on
bringing psychedelic medicines to market through novel delivery systems and psychedelic
assisted psychotherapy. The Company has developed a patent pending thin film oral strip (the
“technology”) which dissolves instantly when placed in the mouth and delivers organic molecules
in precise quantities to the bloodstream, maintaining excellent bioavailability. With this technology,
the Company intends to further develop its IP technology to focus on delivering psychedelic
molecules with an initial focus on psilocybin. Core One also holds an interest in walk-in medical
clinics which maintain a database of over 200,000 patients combined. Through research and
development in these clinics, including the integration of its intellectual property related
to psychedelic treatments and novel drug therapies, the Company intends to work
towards regulatory approval for research that advances psychedelic-derived treatments
for mental health disorders.
Core One Labs Inc.
Joel Shacker
Chief Executive Officer
FOR MORE INFORMATION, PLEASE CONTACT:
info@core1labs.com
1-866-347-5058
Cautionary Disclaimer Statement:
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy
or accuracy of the content of this news release.
Information set forth in this news release contains forward-looking statements that are based on
assumptions as of the date of this news release. These statements reflect management’s current estimates,
beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions
that all forward looking statements are inherently uncertain and that actual performance may be affected
by a number of material factors, many of which are beyond the Company’s control. Such factors include,
among other things: risks and uncertainties relating to the Company’s limited operating history and the need
to comply with environmental and governmental regulations. In addition, marijuana remains a Schedule I
drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the
US Justice Department from spending federal funds to interfere with the implementation of state medical
marijuana laws, this prohibition must be renewed each year to remain in effect. Accordingly, actual and
future events, conditions and results may differ materially from the estimates, beliefs, intentions and
expectations expressed or implied in the forward-looking information. Except as required under applicable
securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking
information. In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and
Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs
and Substances Act (Canada) without a prescription. Health Canada has not approved psilocybin as a drug
for any indication. Core One Labs Inc. does not have any direct or indirect involvement with illegal selling,
production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One
Labs Inc. believes psychedelic substances can be used to treat certain medical conditions, it does not
advocate for the legalization of psychedelics substances for recreational use. Core One Labs Inc. does not
deal with psychedelic substances, except within laboratory and clinical trial settings conducted within
approved regulatory framework
https://www.sedar.com/DisplayCompanyDocuments...o=00031206
TOODLES
4
